Can Moderna's Cancer Vaccine Keep Melanoma From Coming Back?

The headline result came from a trial called KEYNOTE-942, and what matters is what the vaccine was measured against. Not doing nothing after surgery. It was added to pembrolizumab, a PD-1 immunotherapy already used after surgery to lower recurrence risk in eligible high-risk melanoma. So the question was narrower than whether a cancer vaccine works: does adding a personalized vaccine buy protection beyond what pembrolizumab already gives? In that phase 2b trial, it appeared to. The new phase 3 topline makes the signal harder to dismiss, though it leaves the size of the benefit unanswered.

The standard the vaccine had to beat

Blocking the PD-1 checkpoint with pembrolizumab or nivolumab after surgery had become standard for eligible high-risk melanoma before any vaccine came along. At the first KEYNOTE-054 analysis, adjuvant pembrolizumab cut recurrence or death by 43% versus placebo in resected stage III melanoma; a seven-year analysis still favored pembrolizumab, although the relative edge was smaller. CheckMate 238 showed nivolumab kept more people recurrence-free than ipilimumab through nine years of follow-up. PD-1 therapy worked. But recurrences still happened, and whether adjuvant PD-1 therapy lengthens overall survival stayed unsettled in mature trial reports and guidelines. That leftover risk is the gap the vaccine is meant to close.

What the trials found

KEYNOTE-942 randomized 157 people with fully resected stage IIIB to IV melanoma, two-to-one, to the vaccine plus pembrolizumab or pembrolizumab alone. Intismeran is personalized: it's built from sequencing a person's tumor and blood to target the mutations in their own cancer, which takes weeks to manufacture. About a fifth of the combination group recurred or died, versus about two fifths on pembrolizumab alone. At five years, the recurrence and distant-spread advantages descriptively held, with no new safety signal and only an exploratory survival trend.

The bigger update came on August 19, 2026, when Merck and Moderna announced positive topline results from the phase 3 trial, INTerpath-001, in 1,137 people with resected stage IIB through IV melanoma. It met its main recurrence endpoint and a key distant-metastasis endpoint at a planned interim look. The companies released no effect sizes, event counts, or survival curves, and the trial keeps following overall survival. The evidence has moved from one small randomized signal to a positive phase 3 topline, but the size and durability of that phase 3 benefit still wait on the full, peer-reviewed presentation.

There's plausible human immune evidence around the numbers. In the phase 1 KEYNOTE-603 study, mRNA-4157 generated new neoantigen-specific T-cell responses and strengthened existing ones in people with resected solid tumors, including a small melanoma cohort given the combination. The five-year KEYNOTE-942 analysis also reported more T-cell receptor clonality and novel clonotypes with the combination than with pembrolizumab alone. That's human immune evidence, not mouse work, but it shows the vaccine does something plausible rather than proving why the benefit happened.

Where the evidence stops short

The phase 2b trial was open-label, so everyone knew who got the vaccine, which can shape how hard recurrences get chased and reported. It was small. The first recurrence analysis narrowly missed the conventional statistical bar, and the five-year analysis was descriptive, not a formal test. The phase 3 trial was double-blind and much larger, which fixes two of those problems, but only topline phase 3 endpoints have been announced, and the phase 3 results are not peer reviewed yet. Until the full phase 3 data are out, you don't know the size of the benefit, whether it holds across subgroups, how often manufacturing succeeded, or the mature survival effect.

On safety, the phase 2b report found severe treatment-related side effects in about a quarter of the combination group versus about a fifth on pembrolizumab alone. Immune-related side effects ran about the same in both groups, and no life-threatening or fatal events were blamed on the vaccine. The five-year update and the phase 3 topline reported no new safety signals. Reassuring, but rare harms and discontinuation patterns still need the full phase 3 dataset.

The regulatory limit has shifted but not vanished. Intismeran is still investigational, with no approved melanoma use as of August 21, 2026. After the topline result, Merck and Moderna said they plan to present the data and talk to regulators about filing. That isn't approval. Whether it becomes available will depend on the full dataset, regulatory review, and whether personalized manufacturing can work at treatment scale.

What this means for you

The last row matters because "cancer vaccine" invites a hope this evidence doesn't support. Intismeran is a treatment for people who already have a tumor to sequence, not a shot to prevent cancer in the first place.

So the melanoma result is now more than an early signal, but not yet routine care. If your high-risk melanoma has been fully removed, the proven step is standard adjuvant care now, with the vaccine still an investigational add-on moving toward review. A full phase 3 presentation showing a clear effect size and acceptable safety, followed by regulatory approval, would change access; mature survival data would change confidence further. Until then, it's credible and not yet something you can get as standard care.